Concepedia

Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial

Giovanni Grignani, Emanuela Palmerini, Virginia Ferraresi, Lorenzo D’Ambrosio, Rossella Bertulli, Sebastian Dorin Asaftei, Angela Tamburini, Ymera Pignochino, Dario Sangiolo, Emanuela Marchesi,

The Lancet Oncology · 2014 · 335 citations · 37 references

DOIFull text

Open access

Concepts

References

37

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

, , +14

Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

Bernard Escudier, Tim Eisen, Walter M. Stadler et al. · New England Journal of Medicine · 2007 · 4.8K citations · Full text

, , +11

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

Scott M. Wilhelm, Christopher Carter, LiYa Tang et al. · Cancer Research · 2004 · 4K citations · Full text

, , +17

Optimal two-stage designs for phase II clinical trials

Richard Simon · Controlled Clinical Trials · 1989 · 3.6K citations

, , +10

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Robert J. Motzer, Bernard Escudier, Stéphane Oudard et al. · The Lancet · 2008 · 3K citations

, , +11